Skip Nav Destination
Issues
1 April 2022
-
Cover Image
Cover Image
Prostate cancer is the most common cancer among men in the United States. It has a long latent period for precancerous lesions to develop into carcinomas, thus providing opportunities for prevention. Although the most commonly used form of vitamin E, α-tocopherol, was not shown to prevent prostate cancer, other vitamin E forms (γ- and δ-forms of tocopherols and tocotrienols) have shown anti-cancer activities in lab studies. In the article starting on page 233, Wang and colleagues compared the inhibitory activities of the α-, γ- and δ-forms of tocopherols and tocotrienols against six prostate cancer cell lines and found that d-tocotrienol (δ-T3) had the highest activities. δ-T3 (0.05% in the diet) also impeded the formation of prostate adenocarcinoma in prostate specific Pten knockout mice. Proposed mechanisms include the inhibition of cell proliferation and angiogenesis and promotion of apoptosis. δ-T3 is found in rice oil, palm oil, other dietary sources and annatto, a topical plant. The cover image shows the inhibition of angiogenesis in the lesioned gland of the dorsal-lateral-central lobes as determined by C31/Pecam 1 immunochemical staining in mice in the control group (upper left) versus those treated with δ-T3 (upper right). The bottom panels show the blood vessel-rich stroma from mice in the control group (lower left) and the δ-T3-treated group (lower right). - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1940-6207
EISSN 1940-6215
Issue Sections
Highlights from the Literature
Spotlight
Research Briefs
Research Articles
The Association of Predicted Resting Energy Expenditure with Risk of Breast Cancer among Postmenopausal Women in the Women's Health Initiative Cohort
Rhonda S. Arthur; Yasmin Mossavar-Rahmani; Ross L. Prentice; Aladdin H. Shadyab; Juhua Luo; Maryam Sattari; Xiaonan Xue; Victor Kamensky; Guo-Chong Chen; Qibin Qi; Garnet L. Anderson; Sylvia Wassertheil-Smoller; Marian L. Neuhouser; Thomas E. Rohan
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.